A Probe Study of the Safety, Tolerability, and Immunogenicity of a 1-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC-HIV (vCP205) Vaccine in Healthy Adults Who Previously Received a 3-Dose Regimen of MRKAd5, Ad5, or Placebo in Merck V520 Protocols 007 or 012.
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2014
At a glance
- Drugs HIV vaccine vCP205; V 520
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Merck & Co
- 09 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2009 New trial record